Originally aired on: Tuesday, May 29, 2018
The Myers lab has studied microRNAs (miRNA) in Huntington disease (HD) brain, plasma and cerebrospinal fluid (CSF). In a study to assess the potential of miRNAs as biomarkers for disease, we found increased miRNA levels were detected in CSF for carriers of the HD trinucleotide repeat expansion mutation up to twenty years before expected disease onset. Levels increased as proximity to onset decreased suggesting miRNAs may serve as effective biomarkers for prodromal disease long before disease manifestation.
miRNA hold potential as diagnostic biomarkers as well as for evaluating treatments that may postpone HD disease onset and may be relevant to other neurodegenerative diseases.
In this webcast, listeners will learn about: